West Virginia University Logo

Disease Site: Lung

24 protocol(s) meet the specified criteria

  • 4010-01-001A Phase I Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
  • A081105Randomized Study of Erlotinib vs Observation in patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) ALCHEMIST
  • A151216Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
  • CA209743A Phase III, Randomized, Open Label Trial of Nivolumab in combination with Ipilimumab versus Pemetrexed with Cisplatin or Carboplatin as First Line Therapy in unresectable Pleural Mesothelioma
  • CALGB30610Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide.
  • COG-AOST1321Phase 2 Study of Denosumab, a RANK Liggand Antibody, for Recurrent or Refractory Osteosarcoma
  • COG-AOST1421A Phase II Study of Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038, IND# 4308) in Combination with Sargramostim (GM-CSF) in Patients with Recurrent Osteosarcoma
  • D419Q00001A Phase III, Randomized, Multicenter, Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients with Extensive Disease (Stage IV) Small-Cell Lung Cancer (SCLC)
  • D6020C00001A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination with MEDI4736 in Subjects with Advanced Malignancies
  • E4512A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fushion Protein
  • EA5142Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
  • EAY131Molecular Analysis for Therapy Choice (MATCH)
  • GO29432A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer
  • I257814A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing Chemoradiation Therapy.
  • LOXO-TRK-15002A Phase II Basket Study of Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors
  • M16-289A Randomized, Open-label, Multicenter, Phase III Study of Rovalpituzumab Tesirine Compared with Topetecan for High DLL3 Expressing SCLC Subjects with First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy.
  • NRG-CC003Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer
  • NRG-LU002Maintenance Systemic Therapy vs Consolidative Stereotactic Body Radiation Therapy (SBRT) plus Maintenance Systemic Therapy for Limited Metastatic NSCLC: A Phase II/III Trial
  • PRE0504A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung
  • RRX001-211-01A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Readministration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
  • S1400Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer.
  • WVU010516Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer
  • WVU011117Serial ProspECtive bIopsy for Appalachian Lung Cancer Molecular Profiling (SPECIAL) Study
  • X396-CLI-101X-396-CLI-101 Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer